Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(167 produits)
- Bcr-Abl(118 produits)
- EGFR(581 produits)
- FAK(72 produits)
- FLT(86 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(180 produits)
- JAK(243 produits)
- PDGFR(129 produits)
- RAAS(89 produits)
- Src(82 produits)
- Syk(37 produits)
- Thrombine(57 produits)
- VDA(2 produits)
- VEGFR(242 produits)
Affichez 6 plus de sous-catégories
2386 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
(-)-Cevimeline hydrochloride hemihydrate
(-)-Cevimeline HCl hemihydrate, a muscarinic agonist, treats Sjogren's xerostomia. Quick absorption, species-dependent metabolism.Formule :C10H19ClNO1·5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :244.78Protein kinase inhibitor 13
CAS :Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Formule :C19H20FN5OSCouleur et forme :SolidMasse moléculaire :385.458Tyk2-IN-3
CAS :Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).Formule :C25H24N6O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :520.63JBJ-09-063
CAS :JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formule :C31H29FN4O3SCouleur et forme :SolidMasse moléculaire :556.65VEGFR2-IN-1
CAS :VEGFR2-IN-1 is a VEGFR2 inhibitor with antitumor activity used in the study of breast cancer.Formule :C22H18N6SDegré de pureté :98.15%Couleur et forme :SolidMasse moléculaire :398.48EGFR-IN-133
CAS :EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.Formule :C27H29F2N7O3Couleur et forme :SolidMasse moléculaire :537.56FGFR2/3-IN-2
CAS :FGFR2/3-IN-2 (compound 10) is an orally active inhibitor targeting FGFR2 and FGFR3. It exhibits IC50 values of 3.7 nM for FGFR2 and 31.2 nM for FGFR3, with a pre-incubation time of 1 hour. FGFR2/3-IN-2 demonstrates selectivity over FGFR1/4 and other kinases, and does not cause diarrhea or increased serum phosphate in vivo. In the SNU-16 gastric cancer model, FGFR2/3-IN-2 can induce tumor stasis or regression.Formule :C29H23FN6O3Couleur et forme :SolidMasse moléculaire :522.53PF-06263276
CAS :PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).Formule :C31H31FN8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :566.63CEP-11981
CAS :CEP-11981 is an orally active TIE2/pan-VEGFR inhibitor with broad tyrosine kinase inhibitory activity, antitumour and anti-angiogenic, refractory solid tumours.Formule :C28H27N7ODegré de pureté :99.58%Couleur et forme :SolidMasse moléculaire :477.56Multi-kinase inhibitor 4
CAS :Multi-kinase inhibitor 4 (compound 14) serves as an orally effective inhibitor targeting FLT1, KDR, FLT3, FLT4, PDGFRα, and PDGFRβ, exhibiting IC50 values of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, and 0.89 nM respectively. This compound plays a crucial role in cancer research.Formule :C25H24N6O2Couleur et forme :SolidMasse moléculaire :440.50Tyk2-IN-10
CAS :Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.Formule :C25H27N5O3Couleur et forme :SolidMasse moléculaire :445.51EG31
CAS :EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formule :C30H13Br2N3O6Couleur et forme :SolidMasse moléculaire :671.25VEGFR-2-IN-52
CAS :VEGFR-2-IN-52 (compound 14d) serves as a powerful inhibitor of VEGFR-2, exhibiting an IC 50 of 191.1 nM. It effectively reduces the protein expression levels of p-VEGFR-2, MMP9, p-ERK1/2, and p-MEK1. In addition, VEGFR-2-IN-52 demonstrates cytotoxic properties by inducing apoptosis and arresting the cell cycle at the G0/G1 phase, and it enhances the levels of ROS.Formule :C20H25ClN4O2SCouleur et forme :SolidMasse moléculaire :420.96EGFR-IN-161
CAS :EGFR-IN-161 (Compound DD-8) is a potent and reversible inhibitor of the L858R/T790M/C797S mutant EGFR kinase, with an IC50 value of 0.87 nM. EGFR-IN-161 effectively inhibits tumor cell apoptosis, G1 phase arrest, and migration.Formule :C33H36Cl2N8O2Couleur et forme :SolidMasse moléculaire :647.597EGFR-IN-62
EGFR-IN-62: IC50 of 10-242 nM for various EGFR mutations, blocks A549/H1975 cell cycle, induces apoptosis, and inhibits cell motility and proliferation.Formule :C30H33N9O2Couleur et forme :SolidMasse moléculaire :551.64EGFR-IN-132
CAS :EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Formule :C27H31N7O3Couleur et forme :SolidMasse moléculaire :501.58Lucitanib dihydrochloride
CAS :Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.Formule :C26H27Cl2N3O4Couleur et forme :SolidMasse moléculaire :516.42MM-589 TFA
CAS :MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Formule :C30H45F3N8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :686.72Milpecitinib
CAS :Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463Neptinib
CAS :Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.Formule :C22H23ClFN5O2Couleur et forme :SolidMasse moléculaire :443.90EGFR-IN-159
CAS :EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.Formule :C21H23N3O5Couleur et forme :SolidMasse moléculaire :397.424GLPG3312
CAS :GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .Formule :C23H21F2N5O3Degré de pureté :98.53%Couleur et forme :SolidMasse moléculaire :453.44DA-0157
CAS :DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.Formule :C31H43BrN7O2PCouleur et forme :SolidMasse moléculaire :656.597iBFAR2
CAS :iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.
Formule :C19H15F3N2O2Couleur et forme :SolidMasse moléculaire :360.33JAK/HDAC-IN-3
CAS :JAK/HDAC-IN-3 (13a), a dual inhibitor of JAK and HDAC, exhibits IC50 values of 25.36 nM for JAK2, 0.2 μM for HDAC, and 0.43 μM for HDAC1, respectively [1].Formule :C28H37FN6O5SCouleur et forme :SolidMasse moléculaire :588.69Tyk2-IN-15
CAS :Tyk2-IN-15 (Compound 97) is a selective inhibitor of tyrosine kinase 2 (Tyk2) with an IC50 value ≤ 10 nM for Tyk2-JH2. It is utilized in the research of inflammatory and autoimmune diseases [1].Formule :C21H25F2N7OCouleur et forme :SolidMasse moléculaire :429.47SJ11646
CAS :SJ11646 is a Dasatinib-based LCK PROTAC degrader with a DC50 of 0.00838 pM. It exhibits potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples, significantly prolongs LCK signal inhibition, and induces apoptosis in T-ALL cells. SJ11646 binds with high affinity to 51 human kinases, particularly ABL1, KIT, and DDR1. In mouse models of T-ALL, SJ11646 demonstrates exceptional anti-leukemic efficacy.Formule :C36H40ClN9O5SCouleur et forme :SolidMasse moléculaire :746.28Gamendazole
CAS :Gamendazole is a novel drug candidate for male contraception. It has been shown to reduce fertility in male rats without affecting testosterone levels.Formule :C18H11Cl2F3N2O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :415.19BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Formule :C26H36N6O3Couleur et forme :SolidMasse moléculaire :480.6PF-06463922 acetate
CAS :PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.Formule :C23H23FN6O4Couleur et forme :SolidMasse moléculaire :466.46W23-1006
CAS :W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).Formule :C17H12BrN3O5Couleur et forme :SolidMasse moléculaire :418.198Tyk2-IN-14
CAS :Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formule :C22H21N9O2Couleur et forme :SolidMasse moléculaire :443.46EGFR-IN-160
CAS :EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27EGFR-IN-149
CAS :EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Formule :C16H15N3OSCouleur et forme :SolidMasse moléculaire :297.375Clifutinib
CAS :Clifutinib (Compound 9e) is an orally active, selective inhibitor of FMS-like tyrosine kinase 3 (FLT3-ITD) with an IC50 of 15.1 nM. It inhibits FLT3-ITD kinase activity and blocks downstream signaling pathways, including RAS/MAPK, PI3K/AKT, and JAK/STAT5. Clifutinib induces apoptosis in FLT3-ITD mutated acute myeloid leukemia (AML) cells and is a potential candidate for research in relapsed/refractory FLT3-ITD positive AML.
Formule :C29H34N4O4Couleur et forme :SolidMasse moléculaire :502.605JAK1/TYK2-IN-4
CAS :JAK1/TYK2-IN-4 serves as a dual inhibitor targeting both JAK and TYK2, displaying IC50 values of 39 nM and 21 nM, respectively. It is also orally bioavailable [1].Formule :C17H23N7OCouleur et forme :SolidMasse moléculaire :341.41EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formule :C14H11BrN4O2SCouleur et forme :SolidMasse moléculaire :379.23Protein kinase inhibitor 11
CAS :Protein kinase inhibitor 11 (Compound I-96) is an agent that inhibits the activity of PIM-1, CDK-2, GSK-3, and SRC. It shows potential for research in cancer, autoimmune diseases, and neurodegenerative disorders.Formule :C21H18FN5O2SCouleur et forme :SolidMasse moléculaire :423.463FGFR1 inhibitor-15
CAS :FGFR1inhibitor-15 (Compound 23) is an FGFR1 inhibitor with an IC50 value of 27 μM, useful for tumor research.Formule :C17H13FN4OCouleur et forme :SolidMasse moléculaire :308.31Tyk2-IN-17
CAS :Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].Formule :C20H20F2N8OCouleur et forme :SolidMasse moléculaire :426.42Tyrphostin 63
CAS :Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183JP-153
CAS :JP-153 is an inhibitor of Src-FAK-Paxillin signaling. It suppresses Src-dependent phosphorylation of paxillin (Y118) and subsequent activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation of retinal endothelial cells and is applicable in the study of neovascular eye diseases.Formule :C21H19NO5Couleur et forme :SolidMasse moléculaire :365.379CEE321
CAS :CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.Formule :C18H16ClN5OCouleur et forme :SolidMasse moléculaire :353.806DHFR-IN-4
CAS :DHFR-IN-4 is a potent dihydrofolate reductase (DHFR) inhibitor with anti-tumour activity, inhibits EGFR and HER2 and can be used to study pancreatic cancer.Formule :C18H21N5O2SDegré de pureté :99.41%Couleur et forme :SolidMasse moléculaire :371.462,5-Di-tert-butyl-1,4-benzoquinone
CAS :2,5-Di-tert-butyl-1,4-benzoquinone is a potent antibacterial agent found primarily in marine Streptomyces sp. VITVSK1, effective against emerging antibiotic resistance. Additionally, it serves as a powerful inhibitor of RNA polymerase.Formule :C14H20O2Couleur et forme :SolidMasse moléculaire :220.31EGFR-IN-126
CAS :EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.Formule :C28H28BrFN4O3Couleur et forme :SolidMasse moléculaire :567.45FGFR4-IN-10
FGFR4-IN-10 (compound 5a) is a potent, selective FGFR4 inhibitor with IC50 of 70.7 nM, sparing FGFR1-3.Formule :C20H19F3N6O3Couleur et forme :SolidMasse moléculaire :448.4PNU-145156E
CAS :PNU-145156E is a noncytotoxic molecule inhibiting growth and angiogenic factors, suppress tumor angiogenesis, support anti-angiogenic research strategies.Formule :C45H40N10O17S4Couleur et forme :SolidMasse moléculaire :1121.122-Methyl-3-phenylquinoxaline
CAS :2-Methyl-3-phenylquinoxaline (compound 38) serves as an effective inhibitor of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase (PDGF-RTK), exhibiting significant inhibitory activity against the full-length PDGFR kinase in intact cells (IC50 greater than 100 μM).Formule :C15H12N2Couleur et forme :SolidMasse moléculaire :220.27EGFR/VEGFR2-IN-2
EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.Formule :C24H15FO3Couleur et forme :SolidMasse moléculaire :370.37Lazertinib mesylate
CAS :Lazertinib (mesylate) (YH25448 (mesylate); GNS-1480 (mesylate)) is an orally active EGFR inhibitor capable of crossing the blood-brain barrier. It suppresses the p-EGFR, p-AKT, and p-ERK signaling pathways, leading to apoptosis. Lazertinib (mesylate) demonstrates antitumor activity in the H1975-luc BM xenograft model in mice and is applicable for researching non-small cell lung cancer.
Formule :C31H38N8O6SMasse moléculaire :650.75FAK-IN-6
FAK-IN-6: Potent FAK inhibitor (IC50=1.415 nM), anti-cancer, for pancreatic studies.Formule :C25H31ClN5O6PSCouleur et forme :SolidMasse moléculaire :596.04Dual Cathepsin L/JAK-IN-1
CAS :DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).Formule :C19H18ClN5Couleur et forme :SolidMasse moléculaire :351.833NS-062
CAS :NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.Formule :C28H30Cl2F2N6O4Couleur et forme :SolidMasse moléculaire :623.48EGFR-IN-134
EGFR-IN-134 (compound 3f) is a triazolo[3,4-a]quinoline derivative and functions as a potent EGFR inhibitor with an IC50 of 0.023 µM. It induces apoptosis and necrosis in cells, and causes cell cycle arrest in the G2/M and pre-G1 phases. EGFR-IN-134 modulates the expression of apoptosis-regulating proteins by downregulating anti-apoptotic protein Bcl2 and upregulating pro-apoptotic proteins p53, Bax, and caspases 3, 8, and 9, demonstrating significant antiproliferative and anticancer activities.Formule :C36H30N6O5Couleur et forme :SolidMasse moléculaire :626.66Ersentilide
CAS :Ersentilide, a benzamide derivative, functions as both a β1-adrenergic receptor antagonist and an Ikr blocker. It has demonstrated efficacy in animal models of cardiac arrhythmias.Formule :C21H26N4O5SCouleur et forme :SolidMasse moléculaire :446.52Protein kinase inhibitor 10
CAS :Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.Formule :C14H9FN6S2Couleur et forme :SolidMasse moléculaire :344.39HER2-IN-21
CAS :HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447VEGFR/PDGFR-IN-1
CAS :VEGFR/PDGFR-IN-1 (Compound 1) is an inhibitor of VEGFR with an IC50 of 0.4 μM. It can inhibit angiogenesis in HUVEC cells and holds promise for impeding tumor growth and metastasis.Formule :C17H21N5O3Couleur et forme :SolidMasse moléculaire :343.38TZEP7
CAS :TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.Formule :C27H19ClFNSCouleur et forme :SolidMasse moléculaire :443.963LSD1/EGFR-IN-1
CAS :LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.
Formule :C21H20ClN3O4Couleur et forme :SolidMasse moléculaire :413.854SORT1-IN-5
CAS :SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Formule :C19H31NO6SCouleur et forme :SolidMasse moléculaire :401.52FGFR1 inhibitor-17
CAS :FGFR1inhibitor-17 (Compound 92) is a potent inhibitor of FGFR1, with promising applications in cancer research.Formule :C16H13ClN2O3Couleur et forme :SolidMasse moléculaire :316.739TrxR/EGFR-IN-1
CAS :TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.Formule :C24H24AuClFN6O2PCouleur et forme :SolidMasse moléculaire :710.878JAK1-IN-16
JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.Formule :C20H15ClF3N3OSCouleur et forme :SolidMasse moléculaire :437.87EGFR-IN-48
EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.Couleur et forme :SolidTyrosine kinase-IN-9
CAS :Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.Formule :C20H14ClN3O3Couleur et forme :SolidMasse moléculaire :379.796TGF-βRI inhibitor 3
CAS :TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.Formule :C21H21NO4Couleur et forme :SolidMasse moléculaire :351.396lirucitinib
CAS :Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468Ki11502
CAS :Ki11502 is a multi-target receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGFβ/α receptors (with an IC50 of less than 10 nM). It specifically suppresses PDGFβ receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Additionally, Ki11502 induces apoptosis and exhibits significant antiproliferative effects against specific leukemia subgroups, including those with Imatinib-resistant mutations. It is particularly suitable for studying the role of PDGF in vascular diseases and the involvement of proteoglycans in atherosclerosis.Formule :C26H23N3O4SMasse moléculaire :473.54FGFR-IN-6
CAS :FGFR-IN-6 (Compound 5) is an FGFR inhibitor.Formule :C23H22N6O3Couleur et forme :SolidMasse moléculaire :430.46EGFR-IN-125
CAS :EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).Formule :C30H26N8OCouleur et forme :SolidMasse moléculaire :514.58FGFR1 inhibitor-6
FGFR1 inhibitor-6, IC50: 16.31 nM, blocks cell cycle at pro-G1/G2/M and induces apoptosis.Formule :C27H19N5O4S2Couleur et forme :SolidMasse moléculaire :541.6LT-850-166
LT-850-166 is a potent inhibitor of FLT3 and has shown efficacy in overcoming a wide range of FLT3 mutations.Formule :C30H29Cl2N7OCouleur et forme :SolidMasse moléculaire :574.5VEGFR-2/DHFR-IN-1
Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.Formule :C20H18ClNO4Couleur et forme :SolidMasse moléculaire :371.81SJ-C1044
CAS :SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.Formule :C25H14F7N7OCouleur et forme :SolidMasse moléculaire :561.41Sacibertinib
CAS :Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formule :C32H31ClN6O4Couleur et forme :SolidMasse moléculaire :599.08ALK-IN-23
ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.Formule :C26H29ClN8O3SCouleur et forme :SolidMasse moléculaire :569.08VEGFR-2-IN-25
CAS :VEGFR-2-IN-25 (compound 5d) is a potent inhibitor of VEGFR-2 (IC50: 12.1 nM).Formule :C24H22N6O2Couleur et forme :SolidMasse moléculaire :426.47ALK-IN-31
CAS :ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).Formule :C30H33N5O2SCouleur et forme :SolidMasse moléculaire :527.68BTK-IN-10
CAS :BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Formule :C25H24F2N4O2Couleur et forme :SolidMasse moléculaire :450.48EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formule :C16H16N4O2SCouleur et forme :SolidMasse moléculaire :328.39HDHD4-IN-1
CAS :HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Formule :C12H22NO11PCouleur et forme :SolidMasse moléculaire :387.28VEGFR-2-IN-14
VEGFR-2-IN-14 (Compound 5) is a potent inhibitor of VEGFR-2, which inhibits the growth of HepG2 cells in the Pre-G1 phase and induces apoptosis.Formule :C24H23N3O3SCouleur et forme :SolidMasse moléculaire :433.52DDO-02267
CAS :DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.Formule :C18H12N2O7SCouleur et forme :SolidMasse moléculaire :400.362FLT3/TrKA-IN-1
FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.Formule :C28H30N4O2Couleur et forme :SolidMasse moléculaire :454.56JNJ-47117096
CAS :JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.Formule :C21H22N4O2Couleur et forme :SolidMasse moléculaire :362.425FAK inhibitor 6
CAS :Compound 26F: potent enzyme inhibitor (IC50=28.2nM), low cytotoxicity (IC50=3.32μM), induces dose-dependent apoptosis in MDA-MB-231, blocks G0/G1 phase.Formule :C25H24FN5O2SCouleur et forme :SolidMasse moléculaire :477.55EGFR-IN-45
EGFR-IN-45: Strong EGFR/CDK2 inhibitor (IC50s: 0.4 & 1.6 μM), halts cancer cell cycle pre-G1, prompts apoptosis, also targets Topo I/II.Formule :C28H23N7OCouleur et forme :SolidMasse moléculaire :473.53NSC381467
CAS :NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formule :C20H16O7Couleur et forme :SolidMasse moléculaire :368.34VEGFR-2-IN-12
VEGFR-2-IN-12 (compound 6g), a 2-oxoquinoxalinyl-1,2,4-triazole, is a potent inhibitor of VEGFR-2 (IC50: 0.037 μM). VEGFR-2-IN-12 has anti-tumour effects.Formule :C22H24N6O3SCouleur et forme :SolidMasse moléculaire :452.53Pimicotinib hydrochloride
CAS :Pimicotinib hydrochloride is an inhibitor of CSF1R, displaying antitumor activity.Formule :C22H25ClN6O3Couleur et forme :SolidMasse moléculaire :456.925UBX-382
CAS :UBX-382 is an orally administered proteolysis-targeting chimera (PROTAC) designed to target BTK and disrupt B-cell receptor signaling. It demonstrates enhanced degradation of both wild-type and mutant BTK proteins, exhibiting anti-cancer effects in murine xenograft models using TMD-8 cells [1].Formule :C42H44N10O4Couleur et forme :SolidMasse moléculaire :752.86AZD0424
CAS :AZD0424: oral Src/Abl kinase inhibitor; potential anticancer; induces apoptosis, cell cycle arrest in lymphoma.Formule :C25H29ClN6O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.99WDR5-MYC-IN-2
CAS :WDR5-MYC-IN-2 is an inhibitor of the WDR5-MYC protein-protein interaction (PPI) with an IC50 of 0.59 μM. It is utilized in research on MYC-driven cancers and in the development of other potent WDR5-MYC PPI inhibitors.Formule :C22H20BrClN4O4SCouleur et forme :SolidMasse moléculaire :551.84Hypothemycin
CAS :Hypothemycin, a fungal polyketide, inhibits multiple kinases (VEGFR, MEK, FLT-3, PDGFR, ERK) with Kis ranging from 10 nM to 2.4 μM.Formule :C19H22O8Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :378.37EGFR-IN-35
CAS :EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96Ten01
Ten01 exhibits a 5.0 nM inhibition of JAK1 kinase.Formule :C18H20F6N4OCouleur et forme :SolidMasse moléculaire :422.37JAK2-IN-11
CAS :JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formule :C31H31F3N8O4Couleur et forme :SolidMasse moléculaire :639.64LNK01004
CAS :LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.Formule :C26H31N7O2Couleur et forme :SolidMasse moléculaire :473.57
